Chinese Pharma Deal Reaches US$358 Million Upfront

On 6 November, Sino Biopharmaceutical signed a licensing agreement covering six preclinical cancer drugs with Boehringer Ingelheim. The upfront payment is US$358 million, with additional milestone payments possible. HPC can support pharmaceutical sourcing and healthcare-sector partnerships.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.